Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | AKT2 | P31751 | 2/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15466944 | 0.99 | SLC6A4 (0.36) | SLC6A4SLC6A3SLC6A2AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL15466946 | 0.99 | SLC6A4 (0.36) | SLC6A4SLC6A3SLC6A2AKT1AKT2 | |
| SCHEMBL15467274 | 0.83 | AKT1 (0.43) | SLC6A4SLC6A3SLC6A2AKT1AKT2 | |
| SCHEMBL15467270 | 0.83 | AKT1 (0.43) | SLC6A4SLC6A3SLC6A2AKT1AKT2 | |
| SCHEMBL16418774 | 0.83 | NOS3 (0.33) | AKT1AKT2TRPM8 | |
| SCHEMBL15469390 | 0.82 | AKT1 (0.33) | AKT1AKT2TRPM8 | |
| SCHEMBL15469377 | 0.82 | AKT1 (0.33) | AKT1AKT2TRPM8 | |
| SCHEMBL15467738 | 0.82 | TRPV3 (0.38) | SLC6A4SLC6A3SLC6A2TRPM8 | |
| SCHEMBL15467739 | 0.82 | TRPV3 (0.38) | SLC6A4SLC6A3SLC6A2TRPM8 | |
| SCHEMBL16418712 | 0.81 | TAAR1 (0.33) | AKT1AKT2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | SLC6A4 720/4885SLC6A3 1726/4885SLC6A2 1105/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | SLC6A4 720/4885SLC6A3 1726/4885SLC6A2 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.